Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1/Phase 2
INTerpath-005
A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)
- NCT06305767 ↗
- Active, not recruiting
- Merck Sharp & Dohme LLC
- Focused
We haven't built an HCP commentary report on INTerpath-005 (pembrolizumab, intismeran autogene and 1 more in Bladder Cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on INTerpath-005 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- A Phase 1/2 Study of V940 Plus Pembrolizumab With or Without Enfortumab Vedotin in Muscle-Invasive Urothelial Carcinoma (MIUC) (INTerpath-005)
- Phase
- Phase 1/Phase 2
- Status
- Active, not recruiting
- Conditions
- Bladder Cancer
- Interventions
- Pembrolizumab; Intismeran autogene; Placebo; Enfortumab Vedotin; Surgery (RC plus PLND)
- Arms
- Adjuvant Cohort: Pembrolizumab + Intismeran autogene · Experimental
- Adjuvant Cohort: Pembrolizumab + Placebo · Active comparator
- Perioperative Cohort: Pembrolizumab + Intismeran autogene + EV and Surgery · Experimental
- Enrollment
- 230 (estimated)
- Primary outcomes
- Adjuvant Cohort: Disease Free Survival (DFS)
- Perioperative Cohort: Number of Participants Who Experience an Adverse Event (AE)
- Perioperative Cohort: Number of Participants Who Discontinue Study Treatment Due to AE
- Sponsor
- Merck Sharp & Dohme LLC with ModernaTX, Inc.
- Start
- Mar 28, 2024
- Primary completion
- Apr 23, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT06305767 · updated Jan 13, 2026